JP2020507349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507349A5 JP2020507349A5 JP2019565165A JP2019565165A JP2020507349A5 JP 2020507349 A5 JP2020507349 A5 JP 2020507349A5 JP 2019565165 A JP2019565165 A JP 2019565165A JP 2019565165 A JP2019565165 A JP 2019565165A JP 2020507349 A5 JP2020507349 A5 JP 2020507349A5
- Authority
- JP
- Japan
- Prior art keywords
- engineered
- cells
- cell
- expression
- fcrγ chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000822 natural killer cell Anatomy 0.000 claims 82
- 108090000623 proteins and genes Proteins 0.000 claims 55
- 238000000034 method Methods 0.000 claims 41
- 239000000203 mixture Substances 0.000 claims 25
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 18
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 15
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 15
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 230000002068 genetic effect Effects 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 11
- 230000011664 signaling Effects 0.000 claims 11
- -1 Cd161 Proteins 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 230000001419 dependent effect Effects 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 102100022436 CMRF35-like molecule 8 Human genes 0.000 claims 7
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 claims 7
- 101000901669 Homo sapiens CMRF35-like molecule 8 Proteins 0.000 claims 7
- 230000001629 suppression Effects 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 5
- 230000019491 signal transduction Effects 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 4
- 102100029198 SLAM family member 7 Human genes 0.000 claims 4
- 108091023040 Transcription factor Proteins 0.000 claims 4
- 102000040945 Transcription factor Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 claims 3
- 101150069255 KLRC1 gene Proteins 0.000 claims 3
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 claims 3
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 claims 3
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000007783 downstream signaling Effects 0.000 claims 3
- 108091008042 inhibitory receptors Proteins 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102100028572 Disabled homolog 2 Human genes 0.000 claims 2
- 101150016325 EPHA3 gene Proteins 0.000 claims 2
- 102100031780 Endonuclease Human genes 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 2
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 102000005698 Frizzled receptors Human genes 0.000 claims 2
- 108010045438 Frizzled receptors Proteins 0.000 claims 2
- 101710088083 Glomulin Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101000915391 Homo sapiens Disabled homolog 2 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 claims 2
- 101100284157 Hypocrea jecorina (strain QM6a) cel61b gene Proteins 0.000 claims 2
- 229940126049 IMC-1 Drugs 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 108010042918 Integrin alpha5beta1 Proteins 0.000 claims 2
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims 2
- 102000011782 Keratins Human genes 0.000 claims 2
- 108010076876 Keratins Proteins 0.000 claims 2
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 2
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 102100031778 SH2 domain-containing protein 1B Human genes 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 102100035721 Syndecan-1 Human genes 0.000 claims 2
- 108090000058 Syndecan-1 Proteins 0.000 claims 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 102000013127 Vimentin Human genes 0.000 claims 2
- 108010065472 Vimentin Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 102000036215 folic acid binding proteins Human genes 0.000 claims 2
- 108091011001 folic acid binding proteins Proteins 0.000 claims 2
- 230000037433 frameshift Effects 0.000 claims 2
- 150000002270 gangliosides Chemical class 0.000 claims 2
- 238000003119 immunoblot Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 210000005048 vimentin Anatomy 0.000 claims 2
- 102000008682 Argonaute Proteins Human genes 0.000 claims 1
- 108010088141 Argonaute Proteins Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101100107081 Danio rerio zbtb16a gene Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000707218 Homo sapiens SH2 domain-containing protein 1B Proteins 0.000 claims 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 101710097986 SH2 domain-containing protein 1B Proteins 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000007798 antifreeze agent Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060549A JP2023089054A (ja) | 2017-02-09 | 2023-04-04 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
| JP2026013917A JP2026074087A (ja) | 2017-02-09 | 2026-01-30 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457098P | 2017-02-09 | 2017-02-09 | |
| US62/457,098 | 2017-02-09 | ||
| US201762484350P | 2017-04-11 | 2017-04-11 | |
| US62/484,350 | 2017-04-11 | ||
| PCT/US2018/017493 WO2018148462A1 (en) | 2017-02-09 | 2018-02-08 | Engineered natural killer (nk) cells and compositions and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060549A Division JP2023089054A (ja) | 2017-02-09 | 2023-04-04 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507349A JP2020507349A (ja) | 2020-03-12 |
| JP2020507349A5 true JP2020507349A5 (enExample) | 2021-03-18 |
Family
ID=63107061
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565165A Withdrawn JP2020507349A (ja) | 2017-02-09 | 2018-02-08 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
| JP2023060549A Pending JP2023089054A (ja) | 2017-02-09 | 2023-04-04 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
| JP2026013917A Pending JP2026074087A (ja) | 2017-02-09 | 2026-01-30 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060549A Pending JP2023089054A (ja) | 2017-02-09 | 2023-04-04 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
| JP2026013917A Pending JP2026074087A (ja) | 2017-02-09 | 2026-01-30 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11920156B2 (enExample) |
| EP (1) | EP3580341A4 (enExample) |
| JP (3) | JP2020507349A (enExample) |
| CN (1) | CN110546265A (enExample) |
| AU (2) | AU2018219895C1 (enExample) |
| CA (1) | CA3052473A1 (enExample) |
| WO (1) | WO2018148462A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066207B2 (en) | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| CN112839666A (zh) * | 2018-05-14 | 2021-05-25 | 因达普塔治疗公司 | 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群 |
| EP3884041A2 (en) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| KR20240051112A (ko) | 2021-07-01 | 2024-04-19 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 관련 방법 |
| CN114736859B (zh) * | 2022-06-13 | 2022-08-19 | 广东先康达生物科技有限公司 | 一种脐带血nk细胞的培养液及培养方法 |
| US20250375524A1 (en) | 2022-06-30 | 2025-12-11 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| WO2025213127A1 (en) | 2024-04-05 | 2025-10-09 | Indapta Therapeutics, Inc. | Treatment of autoimmune diseases or conditions with natural killer cells |
| WO2025245399A1 (en) | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
| CN119280423A (zh) * | 2024-10-10 | 2025-01-10 | 中南大学 | 一种联合靶向鼻咽癌治疗的载药体系及其制备方法与应用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたａａｖベクター |
| US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
| CA2300957A1 (en) | 1997-08-15 | 1999-02-25 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| WO1999043208A1 (en) | 1998-02-27 | 1999-09-02 | The General Hospital Corporation | The helios gene |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| US6016891A (en) | 1998-08-10 | 2000-01-25 | Sava; John G. | Tree stand harness system |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6168991B1 (en) | 1999-06-25 | 2001-01-02 | Lucent Technologies Inc. | DRAM capacitor including Cu plug and Ta barrier and method of forming |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| WO2001045737A2 (en) | 1999-12-22 | 2001-06-28 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth |
| JP4810042B2 (ja) | 2000-01-21 | 2011-11-09 | バイオヴェックス リミテッド | ヘルペスウイルス株 |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
| NZ527687A (en) | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
| CA2452517A1 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
| WO2003082200A2 (en) | 2002-03-27 | 2003-10-09 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| US20050220818A1 (en) | 2002-06-21 | 2005-10-06 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
| CA2498297A1 (en) | 2002-09-09 | 2004-03-18 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| ATE539162T1 (de) | 2003-03-27 | 2012-01-15 | Ottawa Hospital Res Inst | Mutierte viren der vesikulären stomatitis und deren verwendung |
| MXPA05013879A (es) | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| JP2007511216A (ja) | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| JP2008500832A (ja) | 2004-06-01 | 2008-01-17 | サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール | Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法 |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| ES2678094T3 (es) * | 2004-07-10 | 2018-08-08 | Fox Chase Cancer Center | Líneas de células asesinas naturales genéticamente modificadas |
| JP5525689B2 (ja) | 2004-11-02 | 2014-06-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 過剰増殖性障害を処置するための組成物および方法 |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| EP2963118B1 (en) | 2005-06-01 | 2017-08-09 | California Institute of Technology | Method of targeted gene delivery using viral vectors |
| US8986672B2 (en) | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
| JP5442452B2 (ja) | 2007-02-16 | 2014-03-12 | ウイルツ・バイオロジクス・リミテッド | 単純ヘルペスウイルスおよびウイルス複製法 |
| US8110379B2 (en) * | 2007-04-26 | 2012-02-07 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
| WO2008156655A2 (en) | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
| JP2010533718A (ja) | 2007-07-18 | 2010-10-28 | ジェネラックス・コーポレイション | 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用 |
| WO2009041113A1 (ja) * | 2007-09-28 | 2009-04-02 | Olympus Corporation | Fc受容体遺伝子導入ＮＫ細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法 |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| WO2009139921A2 (en) | 2008-05-16 | 2009-11-19 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| KR101133185B1 (ko) | 2008-07-29 | 2012-04-06 | 서울대학교병원 | 자연살해세포의 증식방법 |
| US8481297B2 (en) | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| JP2012521215A (ja) | 2009-03-26 | 2012-09-13 | アヴァリス・アクチエボラーグ | Ｎｋ細胞の増殖 |
| WO2012061814A1 (en) | 2010-11-05 | 2012-05-10 | Transgenomic, Inc. | Pcr primers and methods for rapid and specific genotyping |
| US10066207B2 (en) * | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| ES2769574T3 (es) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| US9902973B2 (en) * | 2013-04-11 | 2018-02-27 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| US10738278B2 (en) * | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| US20170137784A1 (en) | 2015-03-23 | 2017-05-18 | Cellex Corporation | NK Cell Culture Container And NK Cell Culture Method |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法 |
| EP3828266B1 (en) * | 2015-07-29 | 2022-11-23 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| EP3349770A1 (en) * | 2015-09-14 | 2018-07-25 | Regents of the University of Minnesota | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| US12642852B1 (en) | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3487991B1 (en) | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| EP3539552A1 (en) | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| JP6543375B1 (ja) | 2018-03-27 | 2019-07-10 | 株式会社ガイアバイオメディシン | ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用 |
| CN112839666A (zh) | 2018-05-14 | 2021-05-25 | 因达普塔治疗公司 | 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群 |
| EP3884041A2 (en) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| CN109652379B (zh) | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN114174325A (zh) | 2019-06-04 | 2022-03-11 | 恩卡尔塔公司 | 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 |
-
2018
- 2018-02-08 AU AU2018219895A patent/AU2018219895C1/en active Active
- 2018-02-08 CN CN201880023443.9A patent/CN110546265A/zh active Pending
- 2018-02-08 US US16/484,813 patent/US11920156B2/en active Active
- 2018-02-08 JP JP2019565165A patent/JP2020507349A/ja not_active Withdrawn
- 2018-02-08 EP EP18750838.7A patent/EP3580341A4/en active Pending
- 2018-02-08 WO PCT/US2018/017493 patent/WO2018148462A1/en not_active Ceased
- 2018-02-08 CA CA3052473A patent/CA3052473A1/en active Pending
-
2023
- 2023-04-04 JP JP2023060549A patent/JP2023089054A/ja active Pending
-
2024
- 2024-01-31 US US18/429,244 patent/US12564739B2/en active Active
- 2024-10-25 AU AU2024227637A patent/AU2024227637A1/en active Pending
-
2026
- 2026-01-30 JP JP2026013917A patent/JP2026074087A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7008350B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7783746B2 (ja) | 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成 | |
| JP7664913B2 (ja) | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 | |
| EP3245292B1 (en) | Modified hepatitis post-transcriptional regulatory elements | |
| Campillo-Davo et al. | Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing | |
| JP2021519061A (ja) | 操作された免疫エフェクター細胞およびその使用 | |
| CN114761425A (zh) | 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途 | |
| JP2021522839A5 (enExample) | ||
| JP2021506236A (ja) | 強化された免疫エフェクター細胞およびその使用 | |
| JP2023076572A (ja) | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 | |
| JP2019518804A (ja) | 遺伝的に修飾されたｔリンパ球 | |
| US20220226379A1 (en) | Dnmt3a knock-out stat5 activated genetically engineered t-cells | |
| CN110546265A (zh) | 工程化自然杀伤(nk)细胞及其组合物和方法 | |
| JP2023112191A (ja) | 核酸構築物 | |
| EP3703713A1 (en) | Vectors | |
| CN115835873A (zh) | 用于产生表达重组受体的供体分批细胞的方法 | |
| EP4402177A2 (en) | Compositions of chimeric antigen receptor (car) signaling molecules and uses thereof | |
| Bolsee et al. | Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL | |
| WO2022047419A1 (en) | Novel cell lines, methods of producing natural killer cells and uses thereof | |
| Saranchova et al. | A novel type-2 innate lymphoid cell-based immunotherapy for cancer | |
| KR20250029930A (ko) | 입양 세포 요법에서의 이펙터 세포의 내구성 및 효능 향상 | |
| Zhang et al. | Constitutive STAT3 signaling, in comparison with STAT5, enhances CAR T-cell efficacy and lowers systemic toxicity | |
| WO2022271637A1 (en) | Method for preserving developmental potential of immune cells used for adoptive cellular therapies | |
| Dragon et al. | LMP2A‐Targeting CAR‐T Cells Equipped With Inducible IL‐18 to Address EBV‐Associated Malignancies | |
| CN118742571A (zh) | 用于细胞免疫学的组合物和方法 |